• Home
• Archive
• Rules for Authors
• Policies on Conflict of Interest, Human and animal rights, and Informed Consent
• Peer reviewering policy
• Editorial Board
• Certificate
• Editorial Ethics
• Contacts

Issue 3

Journal for Veterinary Medicine, Biotechnology and Biosafety

Volume 4, Issue 3, September 2018, Page 32

ISSN 2411-3174 (print version) ISSN 2411-0388 (online version)

EFFORTS TOWARDS DEVELOPING AN AFRICAN SWINE FEVER VACCINE

Sunwoo S.-Y. ¹, Pérez-Núñez D. ², Morozov I. ¹, Sánchez E. G. ², Gaudreault N. N. ¹, Madden D. ¹, Trujillo J. ¹, Urbaniak K. ¹, Kim I. J. ¹, Revilla Y. ², Richt J. A. ¹

¹ Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA, e-mail: jricht@vet.k-state.edu

² Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Spain

Download PDF (print version)

Citation for print version: Sunwoo, S.-Y., Pérez-Núñez, D., Morozov, I., Sánchez, E. G., Gaudreault, N. N., Madden, D., Trujillo, J., Urbaniak, K., Kim, I. J., Revilla, Y. and Richt, J. A. (2018) ‘Efforts towards developing an African swine fever vaccine’, Journal for Veterinary Medicine, Biotechnology and Biosafety, 4(3), p. 32.

Download PDF (online version)

Citation for online version: Sunwoo, S.-Y., Pérez-Núñez, D., Morozov, I., Sánchez, E. G., Gaudreault, N. N., Madden, D., Trujillo, J., Urbaniak, K., Kim, I. J., Revilla, Y. and Richt, J. A. (2018) ‘Efforts towards developing an African swine fever vaccine’, Journal for Veterinary Medicine, Biotechnology and Biosafety. [Online] 4(3), p. 32. Available at: http://jvmbbs.kharkov.ua/archive/2018/volume4/issue3/oJVMBBS_2018043_032.pdf

The African swine fever virus (ASFV) causes high morbidity and mortality in swine of the species Sus scrofa, for which there is currently no commercially available vaccine. Recent outbreaks reported in Trans-Caucasus countries, Eastern Europe and China highlight the urgent need to develop effective vaccines against ASFV. We developed an approach based on prime-boost vaccination, combining ASFV antigens encoded by DNA plasmids and recombinant ASFV proteins with the aim to activate both humoral and cellular immunity and tested vaccinated pigs against virulent ASFV challenge. In parallel, gene-deleted ASF viruses to be used as modified live virus vaccines have been developed using CRISP-Cas9 knock-out approaches. The results of this work will provide insights towards the development of rationally designed, safe, efficacious vaccines for ASF.

Keywords: African swine fever, vaccine, DNA, plasmids, recombinant proteins